Patent · US Active

Combined use of PRAME inhibitors and HDAC inhibitors

US8969544B2 · kind B2 · utility

1Cited by

1References

2Claims

0Family size

Inventors

Rene Bernards · Brookline, US
Mirjam Epping · Amsterdam, NL
Liming Wang · Irvine, US

Key dates

Filing date	Mar 10, 2011
Grant date	Mar 3, 2015
Priority date	—
Expiry date	Jul 2, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.